Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05103332 · ClinicalTrials.gov registry record · Phase 2
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 663
- Enrollment target
NCT05103332: Completed Phase 2 study, sponsored by Alnylam Pharmaceuticals.
NCT05103332 is a Phase 2 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 663 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (398% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05103332, a Phase 2 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 663 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.
Primary Outcome
24-hour ABPM device was programmed to take readings every 20 minutes during day (6 am- 9:59 pm) and every 30 minutes during night (10 pm-5:59 am). ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33; 2. the number of successful nighttime readings were ≥11; 3. no more than 3 hours are not represented (i.e.,3 sections of 60 minutes where 0 valid readings were obtained). To summarize 24-hour ABPM, the hourly adjusted mean was calculated. Hourly adjusted mean was t
Interventions
- DRUG Placebo
- DRUG Amlodipine
- DRUG Zilebesiran
- DRUG Olmesartan
- DRUG Indapamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 663 participants |
| Start Date | 2021-11-05 |
| Est. Completion | 2024-09-13 |
| Phase | Phase 2 |
What the finished NCT05103332 record still lists
NCT05103332 is an interventional study that assigns participants to a tested intervention. The registered 663 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (398% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05103332 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05103332 about?
NCT05103332 is a clinical study titled "Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)". The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.
What is the current status of trial NCT05103332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 663 participants. The study started on 2021-11-05. Estimated completion is 2024-09-13.
What interventions are being tested in trial NCT05103332?
The interventions under investigation include: Placebo (DRUG), Amlodipine (DRUG), Zilebesiran (DRUG), Olmesartan (DRUG), Indapamide (DRUG).
Who is sponsoring clinical trial NCT05103332?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05103332's enrollment target sits among peer trials
663 49th of 2000 higher than 1,952 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07164443 · 663 participants · Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
- NCT05254743 · 662 participants · Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI